Alembic Pharmaceuticals has successfully cleared a GMP inspection conducted by the Brazilian Health Regulatory Agency (ANVISA) at its API-III facility in Karakhadi. The inspection, which took place from May 11 to May 15, 2026, resulted in a successful outcome with zero observations. This milestone ensures the facility remains compliant with international quality standards for manufacturing multiple Active Pharmaceutical Ingredients (APIs).
Successful Regulatory Inspection
Alembic Pharmaceuticals has marked a significant quality milestone as its API-III manufacturing facility located in Karakhadi passed the recent Good Manufacturing Practice (GMP) inspection by the Brazilian Health Regulatory Agency (ANVISA). The inspection audit was conducted over a five-day period, concluding on May 15, 2026.
Clean Audit Report
The company confirmed that the audit process was completed successfully without any observations. Receiving a clean report indicates that the facility’s manufacturing processes, quality control systems, and operational protocols align with the stringent requirements set by the Brazilian authorities for the production of multiple APIs.
Strategic Impact
The clearance of this inspection is a positive development for the company’s international operations, reinforcing its commitment to maintaining global quality standards. By meeting these regulatory requirements, Alembic Pharmaceuticals strengthens its ability to maintain its supply chain and commercial presence in the Brazilian market.
Source: BSE
